These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 35798242)

  • 1. Olamkicept(sgp130Fc): The missing trial in Neuromyelitis Optica Spectrum Disorder.
    Magro G
    Clin Immunol; 2022 Aug; 241():109072. PubMed ID: 35798242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Satralizumab might not be enough. Olamkicept (sgp130Fc) in Neuromyelitis Optica Spectrum Disorder.
    Magro G
    Mult Scler Relat Disord; 2022 Sep; 65():104037. PubMed ID: 35835028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Satralizumab: A Review in Neuromyelitis Optica Spectrum Disorder.
    Fung S; Shirley M
    CNS Drugs; 2023 Apr; 37(4):363-370. PubMed ID: 36933107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Local experience of IL-6 pathway inhibition with satralizumab for patients with neuromyelitis optica spectrum disorder].
    Prakhova LN; Krasnov VS; Kasatkin DS; Korobko DS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(7. Vyp. 2):68-72. PubMed ID: 35912559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Satralizumab: an interleukin-6 (IL-6) receptor antagonist for the treatment of neuromyelitis optica spectrum disorders.
    Paton DM
    Drugs Today (Barc); 2021 Mar; 57(3):209-218. PubMed ID: 33729218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting interleukin-6 to treat neuromyelitis optica spectrum disorders: Implications from immunology, the FcRn pathway and clinical experience.
    Sellner J; Sitte HH; Rommer PS
    Drug Discov Today; 2021 Jul; 26(7):1591-1601. PubMed ID: 33781948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting IL-6 receptor in the treatment of neuromyelitis optica spectrum: a review of emerging treatment options.
    Rosso M; Saxena S; Chitnis T
    Expert Rev Neurother; 2020 May; 20(5):509-516. PubMed ID: 32306778
    [No Abstract]   [Full Text] [Related]  

  • 8. Satralizumab in the treatment of neuromyelitis optica spectrum disorder.
    Duchow A; Bellmann-Strobl J
    Neurodegener Dis Manag; 2021 Feb; 11(1):49-59. PubMed ID: 33167776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blockade of IL-6 signaling in neuromyelitis optica.
    Araki M
    Neurochem Int; 2019 Nov; 130():104315. PubMed ID: 30342072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete Relief of Painful Tonic Seizures in Neuromyelitis Optica Spectrum Disorder by Satralizumab Treatment.
    Uzawa A; Mori M; Iwai Y; Masuda H; Kuwabara S
    Intern Med; 2022 Sep; 61(18):2785-2787. PubMed ID: 35135926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Satralizumab for the Treatment of Neuromyelitis Optica Spectrum Disorders.
    Gao Y; Zhang B; Yang J
    Ann Pharmacother; 2021 Sep; 55(9):1167-1171. PubMed ID: 33246373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review of Satralizumab for Neuromyelitis Optica Spectrum Disorder: A New Biologic Agent Targeting the Interleukin-6 Receptor.
    Meher BR; Mohanty RR; Dash A
    Cureus; 2024 Feb; 16(2):e55100. PubMed ID: 38558672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology.
    Fujihara K; Bennett JL; de Seze J; Haramura M; Kleiter I; Weinshenker BG; Kang D; Mughal T; Yamamura T
    Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32820020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe febrile neutropenia associated with satralizumab in an Argentinian neuromyelitis optica spectrum disorder patient.
    Pestchanker C; Diaconchuk M; Lopez P; Montaño MR; Romero W; Zalazar G; Carnero Contentti E
    Mult Scler; 2023 Jan; 29(1):150-153. PubMed ID: 36437566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies.
    Carnero Contentti E; Correale J
    J Neuroinflammation; 2021 Sep; 18(1):208. PubMed ID: 34530847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibody therapy for neuromyelitis optica spectrum disorder: current and future.
    Lin J; Xue B; Li X; Xia J
    Int J Neurosci; 2017 Aug; 127(8):735-744. PubMed ID: 27680606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urosepsis Risk in Neuromyelitis Optica Spectrum Disorder Patients Administered Satralizumab.
    Fujita R; Aratake Y; Nakata K; Fujii C; Kondo T
    Intern Med; 2023 Nov; 62(22):3317-3320. PubMed ID: 37032080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Satralizumab: First Approval.
    Heo YA
    Drugs; 2020 Sep; 80(14):1477-1482. PubMed ID: 32797372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-6 Signaling Blockade Induces Regulatory Plasmablasts in Neuromyelitis Optica Spectrum Disorder.
    Akatani R; Chihara N; Hara A; Tsuji A; Koto S; Kobayashi K; Toda T; Matsumoto R
    Neurol Neuroimmunol Neuroinflamm; 2024 Jul; 11(4):e200266. PubMed ID: 38889374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-IL-6 Therapies for Neuromyelitis Optica Spectrum Disorders: A Systematic Review of Safety and Efficacy.
    Lotan I; McGowan R; Levy M
    Curr Neuropharmacol; 2021; 19(2):220-232. PubMed ID: 32348222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.